KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Total Current Liabilities for 11 consecutive years, with $149.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 69.88% to $149.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.1 million through Dec 2025, up 69.88% year-over-year, with the annual reading at $149.1 million for FY2025, 69.88% up from the prior year.
  • Total Current Liabilities hit $149.1 million in Q4 2025 for CRISPR Therapeutics AG, up from $119.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $150.9 million in Q3 2022 to a low of $83.1 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $116.0 million across 5 years, with a median of $119.0 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: decreased 26.27% in 2023 and later soared 69.88% in 2025.
  • Year by year, Total Current Liabilities stood at $119.9 million in 2021, then grew by 1.02% to $121.1 million in 2022, then fell by 10.17% to $108.8 million in 2023, then fell by 19.31% to $87.8 million in 2024, then skyrocketed by 69.88% to $149.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for CRSP at $149.1 million in Q4 2025, $119.0 million in Q3 2025, and $104.4 million in Q2 2025.